Label Changes for:

Gemzar (Gemcitabine for injection), 1g and 200 mg

May 2013

Changes have been made to the WARNINGS, PRECAUTIONS and ADVERSE REACTIONS sections of the safety label.

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)

 

May 2013

5 WARNINGS AND PRECAUTIONS

5.8 Capillary Leak Syndrome
  • Capillary leak syndrome (CLS) with severe consequences has been reported in patients receiving Gemzar as a single agent or in combination with other chemotherapeutic agents. Discontinue Gemzar if CLS develops during therapy

6 ADVERSE REACTIONS

6.2 Post-Marketing Experience
  • added: Vascular Disorders — Peripheral vasculitis, gangrene, and capillary leak syndrome [see Warnings and Precautions (5.9)]
Hide
(web5)